Cell-Free DNA (cfDNA) Blood Collection Tube Market Report 2025

The cell-free DNA (cfDNA) blood collection tube market size has grown rapidly in recent years. It will grow from $1.17 billion in 2024 to $1.33 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. Growth in the historic period was driven by the increasing prevalence of lifestyle-related disorders, greater emphasis on early genetic screening programs, wider acceptance of blood-based biomarker research, growth in the number of diagnostic laboratories worldwide, and rising awareness of maternal and fetal health monitoring.

The cell-free DNA (cfDNA) blood collection tube market size is expected to see rapid growth in the next few years. It will grow to $2.2 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. Growth in the forecast period is expected to be supported by increasing patient preference for minimally invasive procedures, wider use of cfDNA in transplant monitoring, stronger government initiatives promoting molecular diagnostics, greater demand for efficient sample transport and storage, and expanded insurance coverage for molecular diagnostic tests. Key trends anticipated for the forecast period include advancements in microfluidics-enabled blood collection tubes, innovation in sustainable and eco-friendly tube materials, integration of artificial intelligence for data-driven diagnostics, improvements in prenatal and oncology testing workflows, and the use of companion diagnostics to support targeted therapies.

The rising prevalence of respiratory disorders is expected to drive the growth of the cell-free DNA (cfDNA) blood collection tube market in the coming years. Respiratory disorders are conditions that impact the lungs and other parts of the respiratory system, making it difficult to breathe properly and affecting the delivery of oxygen to the blood or removal of carbon dioxide from the body. The growing prevalence of respiratory disorders is largely attributed to air pollution, which irritates the airways, decreases lung function, and heightens the risk of conditions such as asthma, bronchitis, and chronic obstructive pulmonary disease (COPD). Cell-free DNA (cfDNA) blood collection tubes play a crucial role in managing respiratory disorders by detecting genetic mutations, tracking disease progression, and assessing treatment effectiveness with a simple blood test, reducing the need for invasive lung biopsies. For instance, in December 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported that between October 1 and November 30, 2024, respiratory syncytial virus (RSV) led to an estimated 17,000 to 34,000 hospitalizations. Thus, the increasing occurrence of respiratory disorders is fueling the demand for cfDNA blood collection tubes.

The rising incidence of cancer is expected to drive growth in the cell-free DNA (cfDNA) blood collection tube market in the future. The growing number of cancer cases is linked to lifestyle factors such as poor diet, smoking, and lack of physical activity. cfDNA blood collection tubes are increasingly used in cancer care for liquid biopsies, which allow for the detection of tumor-specific genetic mutations, monitoring of disease progression, evaluation of treatment responses, and identification of resistance mutations through a simple blood test. This method reduces the need for invasive tissue biopsies. For example, in May 2024, the National Cancer Institute, a U.S.-based government agency, projected that the number of cancer survivors in the U.S. would rise to 26 million by 2040, up from 18.1 million in 2022. Therefore, the growing incidence of cancer is driving the demand for cfDNA blood collection tubes.

Key companies operating in the cfDNA blood collection tube market are focusing on automating cfDNA extraction to improve workflow efficiency. Automation of cfDNA extraction involves the use of advanced robotic systems and standardized procedures to isolate cell-free DNA from blood samples with minimal manual intervention, enhancing efficiency, accuracy, and consistency while reducing turnaround times and human error. For example, in September 2023, Yourgene Health plc, a molecular diagnostics company based in the UK, introduced the MagBench Automated DNA Extraction Instrument and Kit. This solution provides a fast, simple, and cost-effective bench-top robotic option optimized for cfDNA extraction in non-invasive prenatal testing (NIPT) workflows. The launch aims to enhance automation in NIPT workflows, delivering higher throughput, reproducibility, and reliability in cfDNA extraction while reducing hands-on time and operational expenses.

Major players in the cell-free DNA (cfDNA) blood collection tube market are Roche Holding AG, Thermo Fisher Scientific Inc., Becton Dickinson (BD), Qiagen N.V., SARSTEDT AG & Co. KG, Guangzhou Improve Medical Technology, Streck Inc., DiaCarta Inc., Zymo Research Corporation, Biomatrica Inc., PreAnalytiX GmbH, Beijing Cowin Bioscience Co.Ltd., Norgen Biotek Corporation, Nonacus Limited, Guangdong Ardent Biomed Co. Ltd, MagBio Genomics Inc., VanGenes, BEAVER, Hebei Xinle Science & Technology Co. Ltd., Nasmed Diagnostics Pvt. Ltd.

North America was the largest region in the cell-free DNA (cfDNA) blood collection tube market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cell-free DNA (cfDNA) blood collection tube report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell-free DNA (cfDNA) blood collection tube market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

A cell-free DNA (cfDNA) blood collection tube is a specialized device designed to collect, stabilize, and transport blood samples for cfDNA analysis. It contains preservatives that protect nucleic acids from degradation and minimize the release of genomic DNA from white blood cells. These tubes support accurate and reliable results in downstream applications such as liquid biopsy, prenatal testing, and cancer diagnostics.

The primary types in the cell-free DNA (cfDNA) blood collection tube market are 5 mL and 10 mL. The 5 mL cfDNA blood collection tube is a smaller-volume option commonly used for individual or routine sample collection. Sample types include plasma, serum, and whole blood. Applications cover in vitro diagnostics and scientific research. Key end-users include diagnostic laboratories, hospitals and clinical centers, genetic diagnostic labs, cancer research centers, research and development institutions, and conventional diagnostic facilities.

The cell-free DNA (cfDNA) blood collection tube market research report is one of a series of new reports that provides cell-free DNA (cfDNA) blood collection tube market statistics, including cell-free DNA (cfDNA) blood collection tube industry global market size, regional shares, competitors with a cell-free DNA (cfDNA) blood collection tube market share, detailed cell-free DNA (cfDNA) blood collection tube market segments, market trends and opportunities, and any further data you may need to thrive in the cell-free DNA (cfDNA) blood collection tube industry. The cell-free DNA (cfDNA) blood collection tube market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell-free DNA (cfDNA) blood collection tube market consists of sales of plasma separation tubes, cryogenic storage systems, and plasma prep centrifugation systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.